AlphAIAlphAI — Financial news for AI agents
investing.comOCT 122 min read$NRIX

Nurix earnings beat by $5.34, revenue topped estimates

Nurix (NRIX) reported Q3 EPS of $4.73, beating estimates by $5.34, with revenue at $673.1M, exceeding expectations of $23.57M. The stock closed at $22.16, down 3.94% over 3 months but up 127.98% year-over-year. InvestingPro rates its financial health as 'weak performance'.

Original reporting
investing.com
Published Oct 12, 2026, 8:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$NRIX
Bullish
high confidence
Mentioned
$NRIX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$NRIXBullishHigh
01

Why it matters

The earnings surprise is likely to trigger short‑term buying, but the company's weak financial health rating may limit upside.

02

Market read

Primary earnings disclosure for a micro‑cap biotech, providing fresh data for traders.

03

What to watch

The weak financial health score and recent price decline could temper enthusiasm.

Relevance 8/10Novelty 8/10Timing: after-hours reaction

Background

Nurix (NASDAQ: NRIX) is a small‑cap biotech that posted a surprise earnings beat for Q3.

Company-level read

Ticker impact

$NRIXBullishHigh confidence
Context

Nurix reported Q3 EPS of $4.73 versus a -$0.61 estimate and revenue of $673.1M versus $23.57M consensus, a material earnings beat.

Expected impact

upward pressure as investors price in the surprise earnings beat

Evidence & confidence

The magnitude of the beat (EPS +$5.34 and revenue >$600M vs $23M) is unprecedented for the stock and should attract short‑term buying.

Market effects

Sector

Biotech sector may see modest uplift as a peer demonstrates strong pipeline execution.

Regional

US biotech market may see slight positive bias.

Global

Limited to investors tracking small‑cap biotech earnings.

Counterpoint

What could challenge this read

Some investors may view the beat as unsustainable and short the stock on valuation concerns.

Key entities

  • company
    Nurix

    Biotech firm reporting Q3 results.

Read at source← All news

StoryNurix Therapeutics posts Q3 2026 profit on $700 million Roche upfront payment

Also covered by

5 outlets

Related articles

OCT 13
$NRIXMedAI 8/10

Nurix Therapeutics 3Q 2026: Revenue $673.1M, EPS $4.73— 10-Q Summary

Nurix Therapeutics reported Q3 2026 revenue of $673.1M, up from $7.9M YoY, driven by Roche license revenue. Net income was $549.8M, a $636.2M swing from a loss last year. Diluted EPS was $4.73. The company advanced clinical trials and expanded partnerships with Roche, Gilead, Sanofi, and Pfizer, receiving $1.2B to date with up to $7.2B in potential milestones and royalties.

tradingview.com2 min
OCT 13
$NRIXHighAI 8/10

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Nurix Therapeutics, Inc. (NRIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobruti

SEC EDGAR 8-K2 min